File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance

TitleOne-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance
Authors
Issue Date2001
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
Citation
Alimentary Pharmacology And Therapeutics, 2001, v. 15 n. 3, p. 403-409 How to Cite?
AbstractAim: To compare 1-week ranitidine bismuth citrate-based (RBC) triple therapy vs. omeprazole-based (O) triple therapy for the eradication of Helicobacter pylori infection in Hong Kong with high prevalence of metronidazole resistance. Methods: Patients with non-ulcer dyspepsia and H. pylori infection were randomized to receive either: (i) RBCCM: ranitidine bismuth citrate (pylorid) 400 mg, clarithromycin 250 mg and metronidazole 400 mg: or (ii) OCM: omeprazole 20 mg: clarithromycin 250 mg and metronidazole 400 mg. each given twice daily for 1 week. Endoscopy (CLO test, histology and culture) and 13C-urea breath test were performed before randomization and 6 weeks after drug treatment. Results: A total of 180 patients were randomized. H. pylori eradication rates (intention-to-treat. n = 180/per protocol, n = 166) were 83%/92% for RBCCM and 66%/70% for OCM (P = 0.01, intention-to-treat and P = 0.001, per protocol, respectively). RBCCM treatment was unaffected by metronidazole susceptibility and achieved a significantly higher eradication rate in metronidazole-resistant cases (89%) than the OCM group (45%, P = 0.0064). Conclusion: One-week ranitidine bismuth citrate-based triple therapy is significantly better than omeprazole-based triple therapy for the eradication of H. pylori infection, especially in metronidazole-resistant cases. It is an effective regimen for the eradication of H. pylori infection in regions with a high prevalence of metronidazole resistance.
Persistent Identifierhttp://hdl.handle.net/10722/78537
ISSN
2015 Impact Factor: 6.32
2015 SCImago Journal Rankings: 2.833
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, BCYen_HK
dc.contributor.authorWong, WMen_HK
dc.contributor.authorWang, WHen_HK
dc.contributor.authorFung, FMYen_HK
dc.contributor.authorLai, KCen_HK
dc.contributor.authorChu, KMen_HK
dc.contributor.authorYuen, STen_HK
dc.contributor.authorLeung, SYen_HK
dc.contributor.authorHu, WHCen_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorLau, GKKen_HK
dc.contributor.authorChan, CKen_HK
dc.contributor.authorLam, SKen_HK
dc.date.accessioned2010-09-06T07:43:58Z-
dc.date.available2010-09-06T07:43:58Z-
dc.date.issued2001en_HK
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2001, v. 15 n. 3, p. 403-409en_HK
dc.identifier.issn0269-2813en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78537-
dc.description.abstractAim: To compare 1-week ranitidine bismuth citrate-based (RBC) triple therapy vs. omeprazole-based (O) triple therapy for the eradication of Helicobacter pylori infection in Hong Kong with high prevalence of metronidazole resistance. Methods: Patients with non-ulcer dyspepsia and H. pylori infection were randomized to receive either: (i) RBCCM: ranitidine bismuth citrate (pylorid) 400 mg, clarithromycin 250 mg and metronidazole 400 mg: or (ii) OCM: omeprazole 20 mg: clarithromycin 250 mg and metronidazole 400 mg. each given twice daily for 1 week. Endoscopy (CLO test, histology and culture) and 13C-urea breath test were performed before randomization and 6 weeks after drug treatment. Results: A total of 180 patients were randomized. H. pylori eradication rates (intention-to-treat. n = 180/per protocol, n = 166) were 83%/92% for RBCCM and 66%/70% for OCM (P = 0.01, intention-to-treat and P = 0.001, per protocol, respectively). RBCCM treatment was unaffected by metronidazole susceptibility and achieved a significantly higher eradication rate in metronidazole-resistant cases (89%) than the OCM group (45%, P = 0.0064). Conclusion: One-week ranitidine bismuth citrate-based triple therapy is significantly better than omeprazole-based triple therapy for the eradication of H. pylori infection, especially in metronidazole-resistant cases. It is an effective regimen for the eradication of H. pylori infection in regions with a high prevalence of metronidazole resistance.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APTen_HK
dc.relation.ispartofAlimentary Pharmacology and Therapeuticsen_HK
dc.rightsAlimentary Pharmacology and Therapeutics. Copyright © Blackwell Publishing Ltd.en_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAnti-Bacterial Agents - pharmacology - therapeutic useen_HK
dc.subject.meshAnti-Infective Agents - pharmacology - therapeutic useen_HK
dc.subject.meshAnti-Ulcer Agents - pharmacology - therapeutic useen_HK
dc.subject.meshBismuthen_HK
dc.subject.meshBreath Testsen_HK
dc.subject.meshCarbon Isotopes - diagnostic useen_HK
dc.subject.meshClarithromycin - pharmacology - therapeutic useen_HK
dc.subject.meshDrug Resistanceen_HK
dc.subject.meshDrug Therapy, Combinationen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHelicobacter Infections - drug therapy - pathologyen_HK
dc.subject.meshHong Kong - epidemiologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMetronidazole - pharmacology - therapeutic useen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshOmeprazole - pharmacology - therapeutic useen_HK
dc.subject.meshPrevalenceen_HK
dc.subject.meshRanitidine - analogs & derivativesen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.subject.meshUrea - analysisen_HK
dc.titleOne-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistanceen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0269-2813&volume=15&spage=403&epage=409&date=2001&atitle=One-week+Ranitidine+Bismuth+Citrate-based+triple+therapy+for+the+eradication+of+Helicobacter+pylori+in+Hong+Kong+with+high+prevalence+of+metronidazole+resistanceen_HK
dc.identifier.emailWong, BCY: bcywong@hku.hken_HK
dc.identifier.emailChu, KM: chukm@hkucc.hku.hken_HK
dc.identifier.emailLeung, SY: suetyi@hkucc.hku.hken_HK
dc.identifier.emailYuen, MF: mfyuen@hkucc.hku.hken_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.identifier.authorityChu, KM=rp00435en_HK
dc.identifier.authorityLeung, SY=rp00359en_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1046/j.1365-2036.2001.00932.xen_HK
dc.identifier.pmid11207516-
dc.identifier.scopuseid_2-s2.0-0035118448en_HK
dc.identifier.hkuros62039en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035118448&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume15en_HK
dc.identifier.issue3en_HK
dc.identifier.spage403en_HK
dc.identifier.epage409en_HK
dc.identifier.isiWOS:000167004400014-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK
dc.identifier.scopusauthoridWong, WM=7403972413en_HK
dc.identifier.scopusauthoridWang, WH=23390847100en_HK
dc.identifier.scopusauthoridFung, FMY=7003833944en_HK
dc.identifier.scopusauthoridLai, KC=7402135595en_HK
dc.identifier.scopusauthoridChu, KM=7402453538en_HK
dc.identifier.scopusauthoridYuen, ST=7103160927en_HK
dc.identifier.scopusauthoridLeung, SY=7202044886en_HK
dc.identifier.scopusauthoridHu, WHC=25932937100en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridLau, GKK=7102301257en_HK
dc.identifier.scopusauthoridChan, CK=7404813824en_HK
dc.identifier.scopusauthoridLam, SK=7402279473en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats